Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.

Conclusion: Physicians were more likely to escalate the dose of IFX, but optimize co-therapy with ADA and ETN. ETN patients had no dose escalation and were less likely to have DMARD and/or glucocorticoid intensification than ADA patients. ETN-treated patients had lower costs compared to IFX patients. PMID: 29296125 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/29296125?dopt=Abstract

Source: Open Rheumatology Journal - January 5, 2018 Category: Rheumatology Tags: Open Rheumatol J Source Type: research